Obesity
Conditions
Keywords
Obesity, Inflammation, Cognitive impairment, Neuroimaging, Magnetic resonance imaging
Brief summary
The rate of obesity in the United States is high and is a risk factor for concurrent cognitive impairment and, in late life, dementias such as Alzheimer's disease. In order to prevent or reduce cognitive impairment, the mechanism underlying the link between obesity and cognitive impairment must be understood. The current study aims to provide preliminary data on whether brain inflammation occurs in obesity and relates to cognitive deficits using magnetic resonance neuroimaging and cognitive testing. It is hypothesized that obese individuals will have greater brain inflammation and lower cognitive function compared to normal-weight individuals. Further, it is predicted that brain inflammation will relate to cognitive function and plasma indicators of inflammation in obese individuals.
Detailed description
Initially, normal-weight or obese potential participants are screened by a phone interview that assesses medical history. Obtainment of informed consent and further screening occurs on the day of the study visit. Participants then undergo a 2 hour oral glucose tolerance test (OGTT) including blood draws for metabolic and inflammatory marker levels in plasma. Lunch is then provided. Participants are then administered 30 minute computer-based cognitive testing from the NIH Toolbox Cognition Battery. After cognitive testing, participants undergo 1.5 hour magnetic resonance imaging (MRI) that includes structural, diffusion tensor, and functional MR imaging.
Interventions
After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
Sponsors
Study design
Masking description
Neuroimaging data was processed using automated methods blind to group membership. Blood samples were analyzed by laboratory personnel blind to group membership.
Intervention model description
This study employed a single group model in which participants with obesity and participants with normal-weight underwent magnetic resonance imaging, blood draws and cognitive assessment.
Eligibility
Inclusion criteria
* Non-obese (body mass index = 18 - 25 kg/m\^2) or Obese (body mass index ≥ 30 kg/m\^2 * Any race or ethnicity * Native English speaker
Exclusion criteria
* Past or current diabetes * Current psychotropic medication use * Past or current neurological illness * Past or current substance or alcohol misuse * Past or current mental illness * Current binge eating disorder * Magnetic resonance imaging contraindications * Pregnancy * Currently lactating * Tobacco use within past month * Over 350 lb
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) | 1.5 hours at the end of one (up to) 8 hour study day that includes all outcome measures | Diffusion Basis Spectrum Imaging (Cross and Song, 2017) is a computational method that will be applied to diffusion tensor images of the brain to estimate putative inflammation-related markers including cellularity and edema in obese and normal-weight individuals. DBSI metrics are quantitative but unitless. Cellularity and edema fractions of the total diffusion signal (including axial, radial, restricted (cellularity) and hindered (edema)) will be estimated in brain white matter tracts. |
| Cognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation Metrics | 40 minutes during one (up to) 8 hour study day that includes all outcome measures; after OGTT and prior to MRI | Cognitive performance including fluid and crystallized cognition composite T-scores from computer-based NIH Cognitive Toolbox assessments (Weintraub et al., 2013) will be assessed in obese and normal-weight individuals. These T-scores will include scores from tasks that assess attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall (see NIH Toolbox Cognitive Battery website). T-scores are corrected for socioeconomic status and their distribution has a mean of 50 and a standard deviation of 10. Higher T-scores indicate better cognitive function. T-scores will be correlated with DBSI-assessed neuroinflammation metrics including restricted fraction (DBSI RF, putative cellularity) and hindered fraction (DBSI HF, putative vasogenic edema) in brain white matter tracts. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Normal-weight Participants who have a body mass index within the normal-weight category.
Oral glucose tolerance test: After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
Cognitive testing: For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
Magnetic resonance imaging: Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately. | 8 |
| Obese Participants who have a body mass index within the obese category.
Oral glucose tolerance test: After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
Cognitive testing: For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
Magnetic resonance imaging: Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately. | 6 |
| Total | 14 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Met exclusion criteria during screeneing on day of study visit. | 2 | 3 |
| Overall Study | Scheduling not possible. | 0 | 1 |
Baseline characteristics
| Characteristic | Normal-weight | Obese | Total |
|---|---|---|---|
| Age, Continuous | 34.9 years STANDARD_DEVIATION 6.6 | 36.5 years STANDARD_DEVIATION 6.8 | 35.6 years STANDARD_DEVIATION 6.5 |
| Body Mass Index | 22.4 kg/m^2 STANDARD_DEVIATION 1.5 | 37.3 kg/m^2 STANDARD_DEVIATION 4.5 | 28.7 kg/m^2 STANDARD_DEVIATION 8.2 |
| Fasting glucose | 87.0 mg/dL STANDARD_DEVIATION 4.6 | 87.2 mg/dL STANDARD_DEVIATION 8 | 87.0 mg/dL STANDARD_DEVIATION 6 |
| Fasting plasma adiponectin | 11.3 ug/mL STANDARD_DEVIATION 5.6 | 10.8 ug/mL STANDARD_DEVIATION 4.9 | 11.1 ug/mL STANDARD_DEVIATION 5.1 |
| Fasting plasma C-reactive protein (CRP) | 1.02 mg/L STANDARD_DEVIATION 0.8 | 4.84 mg/L STANDARD_DEVIATION 3.1 | 2.66 mg/L STANDARD_DEVIATION 2.8 |
| Fasting plasma free fatty acid (FFA) | 0.61 mEq/L STANDARD_DEVIATION 0.27 | 0.81 mEq/L STANDARD_DEVIATION 0.29 | 0.7 mEq/L STANDARD_DEVIATION 0.29 |
| Fasting plasma ghrelin | 1498.5 pg/mL STANDARD_DEVIATION 568.6 | 914.8 pg/mL STANDARD_DEVIATION 261.7 | 1248.4 pg/mL STANDARD_DEVIATION 538.8 |
| Fasting plasma insulin | 5.28 uU/mL STANDARD_DEVIATION 3.73 | 15.62 uU/mL STANDARD_DEVIATION 10.82 | 9.71 uU/mL STANDARD_DEVIATION 9 |
| Fasting plasma interleukin-10 (IL-10) | 1.85 pg/mL STANDARD_DEVIATION 1.38 | 1.97 pg/mL STANDARD_DEVIATION 0.75 | 1.9 pg/mL STANDARD_DEVIATION 1.12 |
| Fasting plasma leptin | 19.9 ug/L STANDARD_DEVIATION 13.4 | 110 ug/L STANDARD_DEVIATION 49.7 | 58.5 ug/L STANDARD_DEVIATION 56.4 |
| Fasting plasma monocyte chemoattractant protein-1 (MCP-1) | 140.9 pg/mL STANDARD_DEVIATION 37 | 160.3 pg/mL STANDARD_DEVIATION 40.1 | 149.2 pg/mL STANDARD_DEVIATION 38.2 |
| Fasting plasma tumor necrosis factor-alpha (TNF-alpha) | 0.69 pg/mL STANDARD_DEVIATION 0.16 | 0.84 pg/mL STANDARD_DEVIATION 0.16 | 0.75 pg/mL STANDARD_DEVIATION 0.17 |
| HbA1c | 5.1 percentage of glycosylated hemoglobin STANDARD_DEVIATION 0.1 | 5.1 percentage of glycosylated hemoglobin STANDARD_DEVIATION 0.4 | 5.1 percentage of glycosylated hemoglobin STANDARD_DEVIATION 0.2 |
| Homeostatic measure of insulin resistance (HOMA-IR) | 1.21 unitless STANDARD_DEVIATION 0.79 | 3.47 unitless STANDARD_DEVIATION 2.56 | 2.18 unitless STANDARD_DEVIATION 2.05 |
| Race/Ethnicity, Customized Asian, non-Hispanic | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Black, non-Hispanic | 1 Participants | 2 Participants | 3 Participants |
| Race/Ethnicity, Customized White, non-Hispanic | 6 Participants | 4 Participants | 10 Participants |
| Region of Enrollment United States | 8 participants | 6 participants | 14 participants |
| Sex: Female, Male Female | 6 Participants | 5 Participants | 11 Participants |
| Sex: Female, Male Male | 2 Participants | 1 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 6 |
| other Total, other adverse events | 0 / 8 | 0 / 6 |
| serious Total, serious adverse events | 0 / 8 | 0 / 6 |
Outcome results
Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI)
Diffusion Basis Spectrum Imaging (Cross and Song, 2017) is a computational method that will be applied to diffusion tensor images of the brain to estimate putative inflammation-related markers including cellularity and edema in obese and normal-weight individuals. DBSI metrics are quantitative but unitless. Cellularity and edema fractions of the total diffusion signal (including axial, radial, restricted (cellularity) and hindered (edema)) will be estimated in brain white matter tracts.
Time frame: 1.5 hours at the end of one (up to) 8 hour study day that includes all outcome measures
Population: Data from 8 individuals with normal-weight and 6 individuals with obesity were included in baseline analyses. Five individuals were enrolled in the study but their data was not collected due to meeting exclusion criteria. One individual was enrolled but could not be scheduled for the study and therefore did not contribute data.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Normal-weight | Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) | DBSI restricted fraction (cellularity) | .0468 unitless | Standard Deviation 0.0024 |
| Normal-weight | Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) | DBSI hindered fraction (vasogenic edema) | .176 unitless | Standard Deviation 0.013 |
| Obese | Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) | DBSI hindered fraction (vasogenic edema) | .186 unitless | Standard Deviation 0.014 |
| Obese | Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) | DBSI restricted fraction (cellularity) | .0492 unitless | Standard Deviation 0.0034 |
Cognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation Metrics
Cognitive performance including fluid and crystallized cognition composite T-scores from computer-based NIH Cognitive Toolbox assessments (Weintraub et al., 2013) will be assessed in obese and normal-weight individuals. These T-scores will include scores from tasks that assess attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall (see NIH Toolbox Cognitive Battery website). T-scores are corrected for socioeconomic status and their distribution has a mean of 50 and a standard deviation of 10. Higher T-scores indicate better cognitive function. T-scores will be correlated with DBSI-assessed neuroinflammation metrics including restricted fraction (DBSI RF, putative cellularity) and hindered fraction (DBSI HF, putative vasogenic edema) in brain white matter tracts.
Time frame: 40 minutes during one (up to) 8 hour study day that includes all outcome measures; after OGTT and prior to MRI
Population: Two individuals in the normal-weight group were not native English speakers and their cognitive data is not included. A complete set of fluid cognition measures was not collected from one normal-weight participant and their fluid cognition data is not included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Normal-weight | Cognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation Metrics | Crystallized Cognition | 60.3 T-score | Standard Deviation 6.9 |
| Normal-weight | Cognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation Metrics | Fluid Cognition | 54.4 T-score | Standard Deviation 6.7 |
| Obese | Cognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation Metrics | Crystallized Cognition | 53.3 T-score | Standard Deviation 9 |
| Obese | Cognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation Metrics | Fluid Cognition | 59.3 T-score | Standard Deviation 7.4 |
Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.
Fasting plasma insulin, a measure of insulin resistance in which higher levels may reflect greater effort to maintain glucose homeostasis, was measured by radioimmunoassay. Normal fasting plasma insulin levels are \< 25 uU/mL.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Normal-weight | Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals. | 5.28 uU/mL | Standard Deviation 3.73 |
| Obese | Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals. | 15.62 uU/mL | Standard Deviation 10.82 |
Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.
Fasting plasma leptin, a hormone related to adipose tissue mass such that higher levels reflect greater adipose tissue mass, was measured by radioimmunoassay. For body mass index (BMI) in normal-weight (18.5-24.9 kg/m\^2), leptin reference range = 1.8-24.2 ug/L in females and 0.2-7.7 in males. For BMI in individuals with obesity, leptin reference range = 10.6-141 in females and 3.2-135 in males.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Normal-weight | Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals. | 19.9 ug/L | Standard Deviation 13.4 |
| Obese | Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals. | 110 ug/L | Standard Deviation 49.7 |
Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.
Fasting plasma ghrelin, a hormone related to hunger in which higher levels may signal the stomach is empty and it is time to eat, was measured by radioimmunoassay. Plasma ghrelin levels tend to be lower in people with obesity. There is no established normal range for fasting plasma ghrelin levels as assessed by radioimmunoassay.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Normal-weight | Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals. | 1498.5 pg/mL | Standard Deviation 568.6 |
| Obese | Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals. | 914.8 pg/mL | Standard Deviation 261.7 |
Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.
Homeostatic measure of insulin resistance (HOMA-IR) where higher scores indicate greater insulin resistance, or diminished maintenance of glucose homeostasis by insulin. HOMA-IR was calculated according to the formula: fasting insulin (uU/L) \* fasting glucose (nmol/L)/22.5 A HOMA-IR score \>2.5 indicates insulin resistance.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Normal-weight | Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals. | 1.21 HOMA-IR score | Standard Deviation 0.79 |
| Obese | Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals. | 3.47 HOMA-IR score | Standard Deviation 2.56 |
Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals
Fasting plasma interleukin (IL)-10, an anti-inflammatory cytokine important for immune response. IL-10 was measured using high-sensitive enzyme-linked immuno-absorbent assay (ELISA). Normal reference ranges for IL-10 have not been established and better or worse levels depend on disease state.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Normal-weight | Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals | 1.85 pg/mL | Standard Deviation 1.38 |
| Obese | Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals | 1.97 pg/mL | Standard Deviation 0.75 |
Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals
Fasting plasma adiponectin, an anti-inflammatory cytokine important for immune response. Adiponectin was measured using radioimmunoassay. Normal reference ranges for adiponectin is 2.5-21.1 ug/mL. Lower levels of adiponectin tend to be associated with worse metabolic health and higher body mass index.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Normal-weight | Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals | 11.3 ug/mL | Standard Deviation 5.6 |
| Obese | Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals | 10.8 ug/mL | Standard Deviation 4.9 |
Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals
Fasting plasma tumor necrosis factor (TNF)-alpha, a pro-inflammatory cytokine important for systemic inflammation. TNF-alpha was measured using high-sensitive enzyme-linked immuno-absorbent assay (ELISA). Normal TNF-alpha levels range from non-detectable to 8.1 pg/mL and tend to be higher in people with obesity compared to normal-weight.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Normal-weight | Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals | 0.69 pg/mL | Standard Deviation 0.16 |
| Obese | Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals | 0.84 pg/mL | Standard Deviation 0.16 |
Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals
Fasting plasma monocyte chemoreactant protein (MCP)-1, a pro-inflammatory chemokine important for immune response and inflammation. MCP-1 was measured using enzyme-linked immuno-absorbent assay (ELISA). Normal reference ranges for MCP-1 have not been established but higher levels tend to be associated with higher body mass index.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Normal-weight | Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals | 140.9 pg/mL | Standard Deviation 37 |
| Obese | Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals | 160.3 pg/mL | Standard Deviation 40.1 |
Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals
Fasting plasma high-sensitive C-reactive protein (CRP), where higher levels may reflect greater low-grade inflammation. High-sensitive CRP was measured using high-sensitive CRP turbidimetry assay. Higher high-sensitive CRP levels may reflect greater risk for cardiovascular disease. Normal range for hs-CRP is usually below 1 mg/L.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Normal-weight | Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals | 1 mg/L | Standard Deviation 0.8 |
| Obese | Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals | 4.8 mg/L | Standard Deviation 3.1 |